These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25225797)

  • 1. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
    Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
    PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
    Kuang Y; Xu H; Lu F; Meng J; Yi Y; Yang H; Hou H; Wei H; Su S
    Cancer Sci; 2021 Jan; 112(1):231-242. PubMed ID: 33091189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM2B mediates the Wnt/β-catenin pathway through transcriptional activation of PKMYT1 via microRNA-let-7b-5p/EZH2 to affect the development of non-small cell lung cancer.
    Zhang X; Yin Z; Li C; Nie L; Chen K
    Exp Cell Res; 2022 Aug; 417(2):113208. PubMed ID: 35580699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells.
    Tzatsos A; Paskaleva P; Lymperi S; Contino G; Stoykova S; Chen Z; Wong KK; Bardeesy N
    J Biol Chem; 2011 Sep; 286(38):33061-9. PubMed ID: 21757686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of EZH2 expression in myelodysplastic syndromes.
    Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
    Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KDM2B is involved in the epigenetic regulation of TGF-β-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines.
    Wanna-Udom S; Terashima M; Suphakhong K; Ishimura A; Takino T; Suzuki T
    J Biol Chem; 2021; 296():100213. PubMed ID: 33779563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.
    Kottakis F; Polytarchou C; Foltopoulou P; Sanidas I; Kampranis SC; Tsichlis PN
    Mol Cell; 2011 Jul; 43(2):285-98. PubMed ID: 21777817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection.
    Sourvinos G; Morou A; Sanidas I; Codruta I; Ezell SA; Doxaki C; Kampranis SC; Kottakis F; Tsichlis PN
    PLoS Pathog; 2014 May; 10(5):e1004136. PubMed ID: 24830456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
    Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Alkahtani S; Alarifi S; Tsichlis PN; Kampranis SC; Stournaras C
    Cell Physiol Biochem; 2018; 47(1):368-377. PubMed ID: 29772566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells.
    Kottakis F; Foltopoulou P; Sanidas I; Keller P; Wronski A; Dake BT; Ezell SA; Shen Z; Naber SP; Hinds PW; McNiel E; Kuperwasser C; Tsichlis PN
    Cancer Res; 2014 Jul; 74(14):3935-46. PubMed ID: 24853546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
    Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Tsichlis PN; Kampranis SC; Stournaras C
    Biochim Biophys Acta Mol Cell Res; 2018 Apr; 1865(4):587-597. PubMed ID: 29408056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
    Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
    Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
    Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q
    Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
    Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
    Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
    Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
    Mu W; Starmer J; Yee D; Magnuson T
    Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.